Technical update on transcatheter arterial chemoembolization

Abstract

Transcatheter arterial chemoembolization has become an established drug delivery system for palliative or bridging treatment of hepatocellular carcinoma. Over the last two decades, various research and developments have taken place to improve the transcatheter arterial chemoembolization procedure from both a clinical and a technical perspective. This review article aims to provide an update on the technical developments over the last decade.

Keywords

Transcatheter arterial chemoembolization / Doxorubicin / bead / cisplatin

References

[1] Guan YS,Wang MQ.Transcatheter arterial chemoembolization: history for more than 30 years..ISRN Gastroenterol2012;2012:480650 PMCID:PMC3433134

[2] Friedman MA,Cassidy MJ.Therapy for hepatocellular cancer with intrahepatic arterial adriamycin and 5-fluorouracil combined with whole-liver irradiadiation: a Northern California Oncology Group study..Cancer Treat Rep1979;63:1885-8

[3] Lammer J,Vogl T,Denys A.Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study..Cardiovasc Intervent Radiol2010;33:41-52 PMCID:PMC2816794

[4] Llovet JM.Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolisation improves survival..Hepatology2003;37:429-42

[5] Puppala S,Yap KS,Wah T.Hepatocellular carcinoma: modern image-guided therapies..Postgrad Med J2016;92:165-71

[6] Raoul JL,Bretagne JF,Duvauferrier R.Chemoembolisation of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin..Cancer1992;70:585-90

[7] Kang YJ,Kim JK,Kim HO.Conventional versus small doxorubicin-eluting bead transcatheter arterial chemoembolization for treating barcelona clinic liver cancer stage 0/A hepatocellular carcinoma..Cardiovasc Intervent Radiol2019;Epub ahead of print [PMID: 31646378 DOI: 10.1007/s00270-019-02349-9]

[8] Puppala S.Kessel D.Management of Post-embolization Syndrome..Transcatheter Embolization and Therapy. Techniques in Interventional Radiology.2010;LondonSpringer

[9] Zou JH,Ren ZG.Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma: a meta-analysis..J Dig Dis2016;17:510-7

[10] Kloeckner R,Prinz F,Ruckes C.Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma..BMC Cancer2015;15:465 PMCID:PMC4460638

[11] Li H,Duan M.Drug-eluting bead transarterial chemoembolization (TACE) vs conventional TACE in treating hepatocellular carcinoma patients with multiple conventional TACE treatments history: a comparison of efficacy and safety..Medicine (Baltimore)2019;98:e15314 PMCID:PMC6571239

[12] Llovet JM,Bruix J.Prognosis of hepatocellular carcinoma: the BCLC staging classification..Semin Liver Dis1999;19:329-38

[13] Affonso BB,da Motta Leal Filho JM,Falsarella PM.Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging..World J Gastroenterol2019;25:5687-701 PMCID:PMC6785514

[14] Decaens T,Bresson-Hadni S,Gugenheim J.Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma..Liver Transpl2005;11:767-75

[15] Sun Y,Ji H,Li C.Clinical efficacy analysis of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) in primary liver cancer and recurrent liver cancer..J BUON2019;24:1402-7

[16] Shi F,Lian SS,Gou Q.Radiofrequency ablation following downstaging of hepatocellular carcinoma by using transarterial chemoembolization: long-term outcomes..Radiology2019;293:707-15

[17] Xu Z,Zhou L,Zheng S.The combination strategy of transarterial chemoembolization and radiofrequency ablation or microwave ablation against hepatocellular carcinoma..Anal Cell Pathol (Amst)2019;2019:8619096 PMCID:PMC6732647

[18] Albrecht MH,Wichmann JL,Scholtz JE.Dynamic 4D-CT angiography for guiding transarterial chemoembolization: impact on the reduction of contrast material, operator radiation exposure, catheter consumption, and diagnostic confidence..Rofo2018;190:513-20

[19] Hayakawa K,Kirishima T,Shintani H.The incidence of contrast-induced nephropathy (CIN) following transarterial chemoembolisation (TACE) in patients with hepatocellular carcinoma (HCC)..Eur Radiol2014;24:1105-11

[20] Aoe M,Ohki T,Ogura Y.Incidence and risk factors of contrast-induced nephropathy after transcatheter arterial chemoembolization in hepatocellular carcinoma..Clin Exp Nephrol2019;23:1141-6

[21] Sun W,Li X.Case series of liver abscess formation after transcatheter arterial chemoembolization for hepatic tumors..Chin Med J (Engl)2017;130:1314-9 PMCID:PMC5455041

[22] Fohlen A,Kobeiter H,Pelage JP.Transarterial chemoembolization (TACE) in the management of hepatocellular carcinoma: results of a French national survey on current practices..Diagn Interv Imaging2018;99:527-35

[23] Seki A,Kobayashi K.Transcatheter arterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres for 135 hepatocellular carcinoma patients: single-center experience..Cardiovasc Intervent Radiol2011;34:557-65

[24] Gomes AS,Sayre JW,Sadeghi S.Comparison of triple-drug transcatheter arterial chemoembolization (TACE) with single-drug TACE using doxorubicin-eluting beads: long-term survival in 313 patients..AJR Am J Roentgenol2017;209:722-32

[25] Aliberti C,Lonardi S,Vitale A.Transarterial chemoembolization with small drug-eluting beads in patients with hepatocellular carcinoma: experience from a cohort of 421 patients at an Italian Center..J Vasc Interv Radiol2017;28:1495-502

[26] Richter G,Stroszczynski C,Helmberger T.Safety and feasibility of chemoembolization with doxorubicin-loaded small calibrated microspheres in patients with hepatocellular carcinoma: results of the MIRACLE I prospective multicenter study..Cardiovasc Intervent Radiol2018;41:587-93 PMCID:PMC5838148

[27] Burrel M,Forner A,de Lope CR.Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design..J Hepatol2012;56:1330-5

[28] Malagari K,Kiakidis T,Kelekis A.Five-years outcome analysis of 142 consecutive hepatocellular carcinoma patients treated with doxorubicin eluting microspheres 30-60 μm: results from a single-centre prospective phase ii trial..Cardiovasc Intervent Radiol2019;42:1551-62

[29] Malagari K,Filippiadis D.Chemoembolization of hepatocellular carcinoma with HepaSphere™..Hepat Oncol2015;2:147-57 PMCID:PMC6095161

[30] Gjoreski A,Eftimovska-Rogac I.Safety profile and efficacy of chemoembolization with doxorubicin - loaded polyethylene glycol microspheres in patients with hepatocellular carcinoma..Open Access Maced J Med Sci2019;7:742-6 PMCID:PMC6447352

[31] Reicher J,Priona G,Manas DM.Early experience of trans-arterial chemo-embolisation for hepatocellular carcinoma with a novel radiopaque bead..Cardiovasc Intervent Radiol2019;42:1563-70 PMCID:PMC6775038

[32] Orlacchio A,Francioso S,Monti S.Repeated transarterial chemoembolization with degradable starch microspheres (DSMs-TACE) of unresectable hepatocellular carcinoma: a prospective pilot study..Curr Med Imaging Rev2018;14:637-45 PMCID:PMC6110039

[33] Orlacchio A,Roma S,Bosa A.Degradable starch microspheres transarterial chemoembolization (DSMs-TACE) in patients with unresectable hepatocellular carcinoma (HCC): long-term results from a single-center 137-patient cohort prospective study..Radiol Med2019;Epub ahead of print [PMID: 31583558 DOI: 10.1007/s11547-019-01093-x]

[34] Meng XX,Liu HC,Gu YF.Application of side-hole catheter technique for transradial arterial chemoembolization in patients with hepatocellular carcinoma..Abdom Radiol (NY)2019;44:3195-9

[35] Hatanaka T,Kakizaki S.Balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma..World J Hepatol2018;10:485-95 PMCID:PMC6068849

[36] Pung L,Mueller K,Stave C.The role of cone-beam CT in transcatheter arterial chemoembolization forhepatocellular carcinoma: a systematic review and meta-analysis..J Vasc IntervRadiol2017;28:334-41

[37] Kim HC.Role of C-arm cone-beam CT in chemoembolization for hepatocellular carcinoma..Korean J Radiol2015;16:114-24 PMCID:PMC4296258

[38] Loffroy R,Cherblanc V.C-arm dual-phase cone-beam CT: a revolutionary real-time imaging modality to assess drug-eluting beads TACE success in liver cancer patients..Quant Imaging Med Surg2013;3:196-9 PMCID:PMC3759134

[39] Ford J.Transradial approach for interventional oncology: an interview with Darren Klass, MD..Intervent Oncol 360.2016;4:E55-60Available from: https://www.iolearning.com/article/transradial-approach-interventional-oncology-interview-darren-klass-md. [Last accessed on 31 Dec 2019]

[40] Valgimigli M,Calabró P,Leonardi S.Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial..Lancet2015;385:2465-76

[41] Chen O,Acholonu M,Verma S.Comparison of standard catheters versus radial artery-specific catheter in patients whounderwent coronary angiography through transradial access..Am J Cardiol2016;118:357-61

[42] Chen YP,Zou Y.Recent advances on polymeric beads or hydrogels as embolization agents for improved transcatheter arterial chemoembolization (TACE)..Front Chem2019;7:408 PMCID:PMC6560223